RSPO2 and neoplasm: For example, an anti-RPSO1 mAb has been shown to reduce tumor growth in an ovarian model, treatment with an anti-RSPO2 mAb reduced tumor growth in both pancreatic and colon cancer models, and an anti-RPSO3 mAb showed significant anti-tumor activity across multiple tumor models, including ovarian, colorectal and non-small cell lung cancers [249].